慢性阻塞性肺疾病患者侵袭性肺曲霉病的诊断标准
全球慢性阻塞性肺疾病(COPD)患者超过4亿,急性加重疾病负担重。COPD住院急性加重患者侵袭性肺曲霉病(IPA)总体发生率仅1%至4%,但某些因素显著增加风险。国际专家组基于文献与共识制定非机械通气COPD患者IPA诊断标准,并经德尔菲法进一步评估。
要点
- COPD住院急性加重且具备两项及以上临床危险因素时应启动CT和微生物学检查。
- 诊断需结合高危COPD、相容影像学异常及任何两项曲霉阳性检测结果。
- 该诊断标准足以启动抗真菌治疗或纳入IPA临床/流行病学研究。
核心结论
- 高危COPD住院急性加重患者结合相容影像学及两项曲霉阳性检测可确立IPA诊断。
研究设计与样本
- 国际专家组基于现有文献与共识制定初步诊断推荐,并经德尔菲法由其他专家进一步评估。
主要发现
- COPD住院急性加重患者IPA总体发生率为1%至4%。
- 损害曲霉防御的危险因素包括全身或高剂量吸入糖皮质激素、支气管扩张症、糖尿病、心血管疾病及长期抗生素疗程。
关键数值与推荐
- COPD住院急性加重伴两项及以上临床危险因素应行胸部CT。
- 应送呼吸道样本(痰、诱导痰或支气管镜样本)行真菌直接镜检、高通量真菌培养及最好行曲霉PCR;支气管镜样本还应行曲霉抗原(半乳甘露聚糖)。
- 应送血清样本行半乳甘露聚糖和曲霉IgG检测。
- 高危COPD患者结合相容影像学异常及任何两项曲霉阳性检测(两份样本或同一呼吸道样本的不同检测)足以确立IPA诊断。
临床怎么用
- 对具备两项及以上危险因素的COPD住院急性加重患者启动CT和微生物学检查。
- 满足诊断标准者可启动抗真菌治疗和/或纳入IPA临床或流行病学研究。
局限性
- 需额外研究以增强大多数检测在COPD中的性能数据并验证所提出的诊断标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over 400 million people have chronic obstructive pulmonary disease (COPD), with exacerbations representing a major health burden. Although the overall incidence of invasive pulmonary aspergillosis (IPA) in patients with COPD with hospitalised exacerbation is only 1 to 4%, certain factors substantially increase this frequency. Risk factors compromising defences against Aspergillus spp in COPD patients include systemic or high-dose inhaled corticosteroids, comorbidities including bronchiectasis, diabetes, and cardiovascular disease, and prolonged courses of antibiotics. An international group of experts met to develop criteria for diagnosing IPA based on existing literature and consensus in non-ventilated COPD patients. The preliminary diagnostic recommendations were further evaluated by additional experts using the Delphi methodology. A hospitalized exacerbation of COPD with two or more of the above clinical risk factors should prompt 1) a CT scan of the chest, 2) sending a respiratory sample (sputum, induced sputum or bronchoscopy sample) for direct microscopy for fungi, high volume fungal culture and preferably Aspergillus PCR, and if a bronchoscopy sample is obtained then also Aspergillus antigen (galactomannan), 3) a serum sample for galactomannan and Aspergillus IgG. The combination of a high-risk COPD patient, with compatible imaging abnormalities and any two positive tests (two samples or different tests on the same respiratory sample) for Aspergillus is sufficient to establish the diagnosis of IPA with enough confidence to initiate antifungal therapy and/or enroll the patient in a clinical or epidemiological study of IPA in COPD. Additional studies are required to augment performance data for most assays in COPD and validate the proposed diagnostic criteria.
引用
- Denning, Rogers, Takazono, et al. Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients. Am J Respir Crit Care Med. 2026. PMID: 42384914. doi:10.1093/ajrccm/aamag310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。